chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride
ADVIL ALLERGY AND CONGESTION RELIEF (chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride) by GSK is cyclooxygenase inhibitors [moa]. First approved in 2011.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
ADVIL Allergy and Congestion Relief is an oral tablet combining ibuprofen (NSAID), chlorpheniramine maleate (antihistamine), and phenylephrine HCl (decongestant) for symptomatic relief of allergy and cold symptoms. It works through cyclooxygenase inhibition to reduce inflammation and pain while addressing multiple symptom pathways. This combination product targets consumers seeking multi-symptom OTC relief.
Peak lifecycle stage indicates mature, stable brand with established market presence; team focus likely on efficiency and margin defense rather than growth.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ADVIL Allergy and Congestion Relief positions you in a mature, cash-generative OTC brand with strong consumer recognition and retail distribution. Career progression emphasizes commercial excellence, market share defense, and operational efficiency rather than innovation or clinical development.
Worked on ADVIL ALLERGY AND CONGESTION RELIEF at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.